<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043896</url>
  </required_header>
  <id_info>
    <org_study_id>1690/KEPK/XII/2019</org_study_id>
    <nct_id>NCT05043896</nct_id>
  </id_info>
  <brief_title>The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction</brief_title>
  <official_title>The Effect of Combination Therapy Using Li-ESWT (Low Intensity Extracorporeal Shockwave Therapy) and PDE-5 Inhibitor in Patients With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Soetomo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Soetomo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      to compare the effect of combination of li-eswt and pde-5 inhibitor to pde-5 alone in&#xD;
      erectile dysfunction patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing the effect of Combination therapy (Li-ESWT combined with PDE5-inhibitor) vs SIngle&#xD;
      therapy (PDE5-inhibitor) in mild to moderate Erectile Dysfunction patients.&#xD;
&#xD;
      Parameters used for comparation are EHS score, IIEF-5 score, VEGF level and PSV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile Hardness Score (EHS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Developed in 1998, the EHS is a single-item Likert scale that men can use on their own.&#xD;
The tool asks them to consider the question &quot;How would you rate the hardness of your erection?&quot; and select one of the following options:&#xD;
0 Penis does not enlarge&#xD;
Penis is larger, but not hard&#xD;
Penis is hard, but not hard enough for penetration&#xD;
Penis is hard enough for penetration, but not completely hard&#xD;
Penis is completely hard and fully rigid&#xD;
The EHS score was taken pre and post intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF-5) score</measure>
    <time_frame>4 weeks</time_frame>
    <description>IIEF-5 is a tool for ED (Erectile Dysfunction)diagnosis. The possible scores for the IIEF-5 range from 5 to 25, and ED was classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25)&#xD;
IIEF-5 score was taken pre and post intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity (PSV)</measure>
    <time_frame>4 weeks</time_frame>
    <description>PSV was measured in cm/s, by using Doppler Ultrasonography. The probe is located at the penis, to be precise in the penoscrotal junction, to measure the velocity of the blood flow in the cavernous arteries.&#xD;
The test was done in flaccid state of the penis Measurement was taken by an experienced ultrasonographer in the radiology unit. Measurement was taken pre and post intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Endothelial Growth Factor (VEGF) level in plasma</measure>
    <time_frame>4 weeks</time_frame>
    <description>VEGF was measured in pg/ml. VEGF test were done by blood test in the laboratory using the VEGF-A ELISA Kit.&#xD;
Blood for tests were drawn pre and post test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Li-ESWT + tadalafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tadalafil only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Li-ESWT</intervention_name>
    <description>Li-ESWT twice weekly for 4 weeks</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Shockwave Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 2.5Mg Tab</intervention_name>
    <description>tadalafil 2.5mg once daily</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Single Therapy</arm_group_label>
    <other_name>Standard First Line Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to Moderate Erectile dysfunction&#xD;
&#xD;
          -  Married&#xD;
&#xD;
          -  Sexually active&#xD;
&#xD;
          -  Consenting to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychological problems&#xD;
&#xD;
          -  Spinal injury&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Penile anatomy abnormalities&#xD;
&#xD;
          -  Allergic and Contraindications to tadalafil&#xD;
&#xD;
          -  On anti-mitotic drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only for male</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tjahjo Tanojo, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Soetomo General Hospital, Andrology Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>dr. Soetomo General Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>Jawa Timur</state>
        <zip>60286</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Soetomo General Hospital</investigator_affiliation>
    <investigator_full_name>Andrian, dr., Sp.And</investigator_full_name>
    <investigator_title>Resident of Andrology Department, Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Study Protocol Chart</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05043896/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Ethical Clearance</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05043896/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Study Protocols and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05043896/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistics Results</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05043896/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT05043896/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

